61 related articles for article (PubMed ID: 14767009)
1. Labile iron in parenteral iron formulations: a quantitative and comparative study.
Van Wyck D; Anderson J; Johnson K
Nephrol Dial Transplant; 2004 Mar; 19(3):561-5. PubMed ID: 14767009
[TBL] [Abstract][Full Text] [Related]
2. Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival.
Gupta A; Zhuo J; Zha J; Reddy S; Olp J; Pai A
BMC Nephrol; 2010 Aug; 11():16. PubMed ID: 20716362
[TBL] [Abstract][Full Text] [Related]
3. Physicochemical properties of ferumoxytol, a new intravenous iron preparation.
Balakrishnan VS; Rao M; Kausz AT; Brenner L; Pereira BJ; Frigo TB; Lewis JM
Eur J Clin Invest; 2009 Jun; 39(6):489-96. PubMed ID: 19397688
[TBL] [Abstract][Full Text] [Related]
4. Labile iron in parenteral iron formulations: a quantitative and comparative study.
Coyne DW
Nephrol Dial Transplant; 2004 Oct; 19(10):2674-5; author reply 2675-6. PubMed ID: 15388831
[No Abstract] [Full Text] [Related]
5. Pharmaceutical characterization and thermodynamic stability assessment of a colloidal iron drug product: iron sucrose.
Shah RB; Yang Y; Khan MA; Raw A; Yu LX; Faustino PJ
Int J Pharm; 2014 Apr; 464(1-2):46-52. PubMed ID: 24440404
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers.
Danielson BG; Salmonson T; Derendorf H; Geisser P
Arzneimittelforschung; 1996 Jun; 46(6):615-21. PubMed ID: 8767353
[TBL] [Abstract][Full Text] [Related]
7. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress.
Koskenkorva-Frank TS; Weiss G; Koppenol WH; Burckhardt S
Free Radic Biol Med; 2013 Dec; 65():1174-1194. PubMed ID: 24036104
[TBL] [Abstract][Full Text] [Related]
8. Structure, chemistry, and pharmacokinetics of intravenous iron agents.
Danielson BG
J Am Soc Nephrol; 2004 Dec; 15 Suppl 2():S93-8. PubMed ID: 15585603
[No Abstract] [Full Text] [Related]
9. Intravenous ferric carboxymaltose is effective and safe in patients with inflammatory rheumatic diseases.
Salvadori U; Vittadello F; Al-Khaffaf A; Maier A; Cappelletto PC; Daves M; Raffeiner B
Blood Transfus; 2020 May; 18(3):176-181. PubMed ID: 31855154
[TBL] [Abstract][Full Text] [Related]
10. Snapshots of Iron Speciation: Tracking the Fate of Iron Nanoparticle Drugs via a Liquid Chromatography-Inductively Coupled Plasma-Mass Spectrometric Approach.
Neu HM; Alexishin SA; Brandis JEP; Williams AMC; Li W; Sun D; Zheng N; Jiang W; Zimrin A; Fink JC; Polli JE; Kane MA; Michel SLJ
Mol Pharm; 2019 Mar; 16(3):1272-1281. PubMed ID: 30676753
[TBL] [Abstract][Full Text] [Related]
11. Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: Biodistribution after Intravenous Dosing in Rats.
Beekman CR; Matta M; Thomas CD; Mohammad A; Stewart S; Xu L; Chockalingam A; Shea K; Sun D; Jiang W; Patel V; Rouse R
Nanomaterials (Basel); 2017 Dec; 8(1):. PubMed ID: 29283393
[TBL] [Abstract][Full Text] [Related]
12. Comparative Evaluation of U.S. Brand and Generic Intravenous Sodium Ferric Gluconate Complex in Sucrose Injection: In Vitro Cellular Uptake.
Wu M; Sun D; Tyner K; Jiang W; Rouse R
Nanomaterials (Basel); 2017 Dec; 7(12):. PubMed ID: 29244729
[TBL] [Abstract][Full Text] [Related]
13. Practical considerations for iron therapy in the management of anaemia in patients with chronic kidney disease.
Roger SD
Clin Kidney J; 2017 Dec; 10(Suppl 1):i9-i15. PubMed ID: 29225818
[TBL] [Abstract][Full Text] [Related]
14. Physicochemical Characterization of Iron Carbohydrate Colloid Drug Products.
Zou P; Tyner K; Raw A; Lee S
AAPS J; 2017 Sep; 19(5):1359-1376. PubMed ID: 28762128
[TBL] [Abstract][Full Text] [Related]
15. Scientific and Regulatory Considerations for Generic Complex Drug Products Containing Nanomaterials.
Zheng N; Sun DD; Zou P; Jiang W
AAPS J; 2017 May; 19(3):619-631. PubMed ID: 28116676
[TBL] [Abstract][Full Text] [Related]
16. The Labile Side of Iron Supplementation in CKD.
Slotki I; Cabantchik ZI
J Am Soc Nephrol; 2015 Nov; 26(11):2612-9. PubMed ID: 25999405
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics and pharmacodynamics of iron preparations.
Geisser P; Burckhardt S
Pharmaceutics; 2011 Jan; 3(1):12-33. PubMed ID: 24310424
[TBL] [Abstract][Full Text] [Related]
18. Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia.
Hussain I; Bhoyroo J; Butcher A; Koch TA; He A; Bregman DB
Anemia; 2013; 2013():169107. PubMed ID: 24069536
[TBL] [Abstract][Full Text] [Related]
19. Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model.
Toblli JE; Cao G; Oliveri L; Angerosa M
Inflamm Allergy Drug Targets; 2012 Feb; 11(1):66-78. PubMed ID: 22309085
[TBL] [Abstract][Full Text] [Related]
20. Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice.
Bhandari S
Ther Clin Risk Manag; 2011; 7():501-9. PubMed ID: 22241947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
